Welcome to our dedicated page for Compugen SEC filings (Ticker: CGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Compugen Ltd (CGEN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including its ongoing series of Form 6-K current reports. As a foreign private issuer, Compugen uses these filings to furnish investors with financial results, clinical and corporate updates, and details of material agreements.
Recent Form 6-K filings include quarterly financial statements and management’s discussion and analysis, which outline revenues from collaboration and license agreements, research and development expenses, general and administrative costs, and information on cash, cash equivalents, short-term deposits, and investments in marketable securities. These filings help investors understand how Compugen funds its clinical-stage cancer immunotherapy programs and how long its reported cash runway is expected to support operations.
Compugen’s 6-K reports also furnish press releases on key corporate events. Examples include announcements of second and third quarter results, initiation of the MAIA-ovarian platform trial of COM701, pooled analyses of COM701 Phase 1 trials in platinum-resistant ovarian cancer, and presentations of GS-0321 (COM503) trial designs. Another 6-K describes an amendment to the company’s license agreement with a member of the AstraZeneca Group, under which Compugen sold a portion of its royalty interest in rilvegostomig in exchange for an upfront payment and an increased milestone payment tied to Biologics License Application acceptance.
Through Stock Titan, users can review these filings alongside AI-powered summaries that explain the main points of each document, such as changes to collaboration economics, updates on clinical development, and the results of shareholder meetings. The filings page is a central resource for analyzing how Compugen reports its progress, manages its partnerships with AstraZeneca and Gilead, and discloses financial and operational information to the market.
Compugen Ltd. filed a report describing the appointment of Michele Holcomb, Ph.D. as a new independent director to its Board, effective February 11, 2026. She will serve until immediately after the 2026 annual general meeting or until a successor is elected or her office is vacated earlier.
The company highlights Dr. Holcomb’s more than 30 years of experience across biotech, pharmaceuticals, and healthcare services, including senior roles at Cardinal Health, Teva Pharmaceuticals, and McKinsey & Company, as well as current board positions at PureTech Health, Kimball Electronics, and Controlant.
Compugen Ltd. entered into an amendment with MedImmune Limited, part of the AstraZeneca Group, under which it sold to AstraZeneca a portion of its existing royalty interest in the cancer immunotherapy candidate rilvegostomig for a $65 million upfront payment, due within five business days of the
The amendment also increases by $25 million the milestone payment payable to Compugen upon the next milestone, defined as the first acceptance of the Biologics License Application for rilvegostomig.
This transaction shifts part of Compugen’s expected future royalty stream into near-term cash while enhancing the potential size of a key future regulatory milestone payment linked to BLA acceptance.
Compugen Ltd. (CGEN) filed a Form 6-K
The report was signed by Eran Ben Dor, General Counsel, on November 10, 2025. Investors seeking financial details should refer to Exhibit 99.1, which contains the full Q3 2025 results.
Compugen Ltd. (CGEN) filed a Form 6-K noting it issued a press release on October 13, 2025, which is furnished as Exhibit 99.1. With the exception of the third, fourth, and fifth paragraphs of the press release, the information incorporated by reference in this report is also incorporated into the Company’s Registration Statement on Form F-3 (File No. 333-270985).
The report was signed by Eran Ben Dor, General Counsel, on October 14, 2025.
Compugen Ltd. reports that it held its 2025 Annual General Meeting of Shareholders on September 16, 2025. According to the company, all proposals presented to shareholders at the meeting were approved by the required majority, meaning each item on the agenda received sufficient support to pass. The notice of meeting, proxy statement and proxy card had previously been filed with the SEC and are incorporated by reference. The company also states that the information in this report is incorporated by reference into its existing shelf registration statement on Form F-3.